Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast
1993

Study of pS2 Protein in Breast Cancer

Sample size: 47 publication Evidence: moderate

Author Information

Author(s): Y.A. Luqmani, T. Campbell, S. Soomro, S. Shousha, M.C. Rio, R.C. Coombes

Primary Institution: Charing Cross Hospital Medical School

Hypothesis

The expression of pS2 protein increases from normal to benign to cancerous breast cells.

Conclusion

The study found that pS2 is expressed in both invasive and pre-invasive forms of breast cancer, with significant positivity in 63-67% of ductal carcinoma in situ cases.

Supporting Evidence

  • pS2 expression was found in 63-67% of ductal carcinoma in situ cases.
  • Significant pS2 positivity was observed in about 50% of benign proliferative conditions.
  • pS2 was correlated with the presence of progesterone receptor positive cells.

Takeaway

This study looked at a protein called pS2 in breast cancer and found that it shows up more in cancer cells than in normal cells.

Methodology

The study used immunohistochemical techniques on archival paraffin-embedded tissue samples from patients diagnosed with ductal carcinoma in situ.

Limitations

The study had a small sample size and relied on archival material, which may not represent current cases.

Participant Demographics

Patients diagnosed with ductal carcinoma in situ, with a total of 47 biopsies examined.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication